In Phase III trials, Israel’s Teva reported that its Laquinimod oral treatment for multiple sclerosis reduced neuro-degeneration, slowing the progression of locomotor disability in multiple sclerosis patients. Laquinimod might also help treat Crohn’s disease, lupus nephritis, Huntington’s disease and Alzheimer’s.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000882391&fid=1725
Laquinimod reduces brain damage in MS patients
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.